Effects of a long-acting antiarrhythmic agent--QX-572--on therapy resistant ventricular tachyarrhythmias.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000404:Ajmaline / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D002219:Carbamates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003327:Coronary Disease / Q000150:complications; D004351:Drug Resistance; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007263:Infusions, Parenteral; D008012:Lidocaine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications; D010672:Phenytoin / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011802:Quinidine / Q000627:therapeutic use; D013610:Tachycardia / Q000139:chemically induced
D000889:Anti-Arrhythmia Agents; D002219:Carbamates; D000644:Quaternary Ammonium Compounds; D000404:Ajmaline; D010672:Phenytoin; D008012:Lidocaine; D011802:Quinidine; D011342:Procainamide